Hepatoprotective effect of linagliptin against liver fibrosis induced by carbon tetrachloride in mice

Maaly A. Abd Elmaaboud, Haidy Khattab, Shahinaz M. Shalaby

Canadian Journal of Physiology and Pharmacology · 2020 · 13 citations · 26 references

Concepts

Abstract

The current study aimed to investigate linagliptin for its potential role in the prevention of liver fibrosis progression. Balb-C mice were randomly allocated into five groups (10 each): (i) control; (ii) mice were injected intraperitoneally with 50 μL carbon tetrachloride (CCl 4 ) in corn oil in a dose of 0.6 μL/g three times per week for four weeks; (iii) linagliptin was administered orally in a daily dose of 10 mg/kg simultaneously with CCl 4 ; (iv) silymarin was administered orally in a daily dose of 200 mg/kg concomitantly with CCl 4 ; and (v) only linagliptin was administered. Hepatic injury was manifested in the CCl 4 group by elevation of biochemical parameters (alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP)), and hepatic fibrosis was evident histopathologically by increased METAVIR score and immunostaining expression of alpha-smooth muscle actin (α-SMA), as well as increased liver tissue oxidative stress parameters, transforming growth factor-β1 (TGF-β1), and mammalian target of rapamycin (mTOR). Linagliptin was able to stop the progression of liver fibrosis, evident histopathologically with reduced METAVIR score and α-SMA expression. The possible mechanism may be via suppression of oxidative stress, TGF-β1, and mTOR, which was associated with improvement of serum biochemical parameters ALT and AST. In conclusion, linagliptin might help to protect the liver against persistent injury-related consequences.

References

26